Histogenics said last month that it raised $30 million in a private placement it plans to use for a pivotal trial of its NeoCart regenerative knee treatment.
The Waltham, Mass.-based company said the round, of equity, convertible stock and warrants, was led by new institutional investors and some of its existing backers. The cash infusion should be enough to last the company through the middle of 2018, Histogenics said.
